Amid a quarter dominated by mega-cap tech and AI fervor, Pzena Investment Management's value-focused fund highlighted discount retailer Dollar General as a key performer, driven by strong earnings that propelled its stock.
Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.
Investment firm Curreen Capital posted strong 2025 results, crediting its focus on undervalued 'ugly duckling' stocks. The fund's latest letter spotlights VF Corporation (VFC), the embattled owner of Vans and The North Face, as a potential turnaround play despite its shares falling over 20% in the past year.
While broader UK indices face headwinds, a closer look reveals potential in smaller-cap companies. We examine three penny stocks—Alumasc Group, Mercia Asset Management, and Roebuck Food Group—that are navigating economic challenges with distinct strategies and financial profiles.
Investors who held shares in SouthGobi Resources Ltd. (CVE:SGQ) since 2019 have seen a staggering 486% return, a powerful case study in long-term equity investing despite recent volatility.
A catastrophic landslide has torn through the historic Sicilian town of Niscemi, forcing mass evacuations and exposing a legacy of bureaucratic delays and unheeded geological warnings that left the community perilously vulnerable.
The Rafah border crossing between Gaza and Egypt has partially reopened under the terms of the US-brokered ceasefire, permitting a limited number of medical evacuations for the first time in nearly two years, as tens of thousands await passage.
Despite posting strong quarterly earnings, Microsoft's stock suffered its worst single-day drop in years as Wall Street focused on soaring capital expenditures and a slight deceleration in cloud revenue growth, highlighting the intense pressure on tech giants to deliver immediate AI payoffs.
Investment firm Ashva Capital Management outlines its investment case for The Walt Disney Company in its Q4 2025 letter, highlighting the entertainment giant's enduring value proposition amid near-term market volatility.
Investment firm Giverny Capital highlights insurance distributor TWFG as a key holding in its latest letter, revealing a challenging year where its value-focused strategy lagged the AI-fueled market rally.
Investors in lighting specialist FW Thorpe have seen a negative total shareholder return of 25% since 2021, starkly underperforming the broader market's gains. Despite steady revenue growth, the share price decline highlights a disconnect with company fundamentals.
Despite a 14% share price decline over the past quarter, Associated British Foods (LON:ABF) demonstrates robust underlying financial health, driven by strong earnings growth and efficient capital reinvestment, suggesting potential for a market correction.
PepsiCo's CEO expands his tech governance role at IBM, while a new financial chief takes the helm in the critical India region. These moves come as the beverage and snack giant's stock shows resilience, prompting investor analysis of its future direction.
Amidst sluggish sales and intense competition, Target appoints Michael Fiddelke as CEO and refreshes its board, placing store revitalization and operational efficiency at the heart of its turnaround strategy.
As the TSX rides a wave of broad-based earnings optimism, a closer look reveals smaller companies, often miscategorized as 'penny stocks', that combine financial resilience with clear growth trajectories. We examine three such firms with market caps up to CA$700 million.
Bitcoin's sharp decline below critical technical levels has amplified fears of a prolonged bear market, with prominent critics questioning its fundamental value. While some analysts see a buying opportunity, the mood among traders is turning increasingly grim.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
Lithia Motors' shares have retreated over 11% in the past year, sparking debate among investors. A detailed analysis of its discounted cash flow and peer comparisons suggests the auto retailer may be significantly undervalued, trading at a steep discount to its estimated intrinsic value.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
The medtech giant inaugurates a Centre of Excellence in Swords, aiming to accelerate development of its Atellica diagnostic systems and bolster Ireland's life sciences sector amid strategic corporate shifts.
